vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $12.1M, roughly 1.6× TRANSCONTINENTAL REALTY INVESTORS INC). TRANSCONTINENTAL REALTY INVESTORS INC runs the higher net margin — 68.8% vs -90.7%, a 159.5% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 2.3%).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.
NAMS vs TCI — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $12.1M |
| Net Profit | $-17.4M | $8.3M |
| Gross Margin | — | — |
| Operating Margin | -186.1% | -28.9% |
| Net Margin | -90.7% | 68.8% |
| Revenue YoY | 740.1% | 2.3% |
| Net Profit YoY | 55.5% | 7577.8% |
| EPS (diluted) | $-0.15 | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.1M | ||
| Q3 25 | — | $12.8M | ||
| Q2 25 | $19.1M | $12.2M | ||
| Q1 25 | — | $12.0M | ||
| Q4 24 | $12.8M | $11.8M | ||
| Q3 24 | $29.1M | $11.6M | ||
| Q2 24 | — | $11.8M | ||
| Q1 24 | — | $11.9M |
| Q4 25 | — | $8.3M | ||
| Q3 25 | — | $724.0K | ||
| Q2 25 | $-17.4M | $169.0K | ||
| Q1 25 | — | $4.6M | ||
| Q4 24 | $-92.2M | $108.0K | ||
| Q3 24 | $-16.6M | $1.7M | ||
| Q2 24 | — | $1.5M | ||
| Q1 24 | — | $2.5M |
| Q4 25 | — | -28.9% | ||
| Q3 25 | — | -10.9% | ||
| Q2 25 | -186.1% | -6.8% | ||
| Q1 25 | — | -5.3% | ||
| Q4 24 | -338.5% | -14.3% | ||
| Q3 24 | -85.9% | -14.4% | ||
| Q2 24 | — | -9.2% | ||
| Q1 24 | — | -11.2% |
| Q4 25 | — | 68.8% | ||
| Q3 25 | — | 5.6% | ||
| Q2 25 | -90.7% | 1.4% | ||
| Q1 25 | — | 38.5% | ||
| Q4 24 | -721.7% | 0.9% | ||
| Q3 24 | -57.2% | 14.7% | ||
| Q2 24 | — | 12.7% | ||
| Q1 24 | — | 21.4% |
| Q4 25 | — | $0.97 | ||
| Q3 25 | — | $0.08 | ||
| Q2 25 | $-0.15 | $0.02 | ||
| Q1 25 | — | $0.53 | ||
| Q4 24 | $-0.91 | $0.01 | ||
| Q3 24 | $-0.18 | $0.20 | ||
| Q2 24 | — | $0.17 | ||
| Q1 24 | — | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $89.0M |
| Total DebtLower is stronger | — | $210.8M |
| Stockholders' EquityBook value | $778.5M | $846.7M |
| Total Assets | $815.1M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $89.0M | ||
| Q3 25 | — | $82.7M | ||
| Q2 25 | $739.2M | $73.5M | ||
| Q1 25 | — | $88.6M | ||
| Q4 24 | $834.2M | $99.7M | ||
| Q3 24 | $422.7M | $131.6M | ||
| Q2 24 | — | $127.5M | ||
| Q1 24 | — | $130.8M |
| Q4 25 | — | $210.8M | ||
| Q3 25 | — | $223.5M | ||
| Q2 25 | — | $212.4M | ||
| Q1 25 | — | $198.2M | ||
| Q4 24 | — | $181.9M | ||
| Q3 24 | — | $180.3M | ||
| Q2 24 | — | $177.4M | ||
| Q1 24 | — | $178.3M |
| Q4 25 | — | $846.7M | ||
| Q3 25 | — | $838.4M | ||
| Q2 25 | $778.5M | $837.7M | ||
| Q1 25 | — | $837.3M | ||
| Q4 24 | $757.5M | $832.3M | ||
| Q3 24 | $378.9M | $832.2M | ||
| Q2 24 | — | $830.4M | ||
| Q1 24 | — | $828.9M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | $815.1M | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $864.6M | $1.1B | ||
| Q3 24 | $439.2M | $1.1B | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | — | $1.0B |
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.22× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $-2.9M |
| Free Cash FlowOCF − Capex | $-37.8M | — |
| FCF MarginFCF / Revenue | -197.2% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | -0.35× |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.9M | ||
| Q3 25 | — | $8.2M | ||
| Q2 25 | $-37.7M | $-2.9M | ||
| Q1 25 | — | $-7.4M | ||
| Q4 24 | $-37.5M | $1.3M | ||
| Q3 24 | $-12.5M | $13.7M | ||
| Q2 24 | — | $-511.0K | ||
| Q1 24 | — | $3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-37.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-37.5M | — | ||
| Q3 24 | $-12.6M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -197.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -293.5% | — | ||
| Q3 24 | -43.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.35× | ||
| Q3 25 | — | 11.28× | ||
| Q2 25 | — | -17.24× | ||
| Q1 25 | — | -1.61× | ||
| Q4 24 | — | 12.13× | ||
| Q3 24 | — | 8.03× | ||
| Q2 24 | — | -0.34× | ||
| Q1 24 | — | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
